SIR-T Her2xIL13Ra2

SIR-T Her2xIL13Ra2 is a preclinical-stage bispecific cell therapy developed by Angeles Therapeutics. It utilizes the company's proprietary Synthetic Intramembrane Receptor (SIR-T) platform, which is designed to enhance the efficacy and safety of T-cell therapies against solid tumors. This specific candidate is engineered to simultaneously target two tumor-associated antigens: Human Epidermal Growth Factor Receptor 2 (HER2) and Interleukin-13 receptor subunit alpha-2 (IL13Ra2). By employing a dual-targeting approach, the therapy aims to overcome tumor heterogeneity and reduce the risk of antigen escape, common challenges in treating solid malignancies such as glioblastoma or other HER2/IL13Ra2-positive cancers.

Other names

SIR-T HER2 x IL13Ra2SIR-T HER2/IL13Ra2